Robert Sikorski, M.D., Ph.D., serves as consulting Chief Medical Officer at Abintus and also serves as the Managing Director of Woodside Way Ventures. Previously, he was Chief Medical Officer of Five Prime Therapeutics (acquired by Amgen). Earlier in his career, he played a leading role in building MedImmune’s oncology portfolio through internal development, partnering, and acquisitions. Prior to joining Medimmune, he led late-stage clinical development and post-marketing efforts for several commercial drugs and drug candidates at Amgen. Dr. Sikorski began his career as a Howard Hughes Research Fellow and Visiting Scientist at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate Harold Varmus. Additionally, he has served as an editor for the journal Science and Journal of the American Medical Association. Dr. Sikorski obtained his MD and Ph.D. degrees as a Medical Scientist Training Program awardee at the Johns Hopkins School of Medicine.